Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19

Benzinga · 1d ago
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.